Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases

This publication has 71 references indexed in Scilit:

• COX-2 inhibitors
  The Lancet, 1999
• CYCLOOXYGENASES 1 AND 2
  Annual Review of Pharmacology and Toxicology, 1998
• A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors
  Journal of Biological Chemistry, 1996
• The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
  Nature Structural & Molecular Biology, 1995
• Different Intracellular Locations for Prostaglandin Endoperoxide H Synthase-1 and −2
  Journal of Biological Chemistry, 1995
• Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.
  Circulation, 1993
• The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.
  Journal of Clinical Investigation, 1975
• Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
  Nature New Biology, 1971
• Pharmakologisches über Aspirin (Acetylsalicylsäure)
  Pflügers Archiv - European Journal of Physiology, 1899
• XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire
  Philosophical Transactions of the Royal Society of London, 1763